Core Insights - Rapport Therapeutics announced new data from the Phase 2a trial of RAP-219, highlighting its early onset of action and consistent efficacy in treating drug-resistant focal onset seizures [1][2][3] Efficacy and Safety Data - RAP-219 showed a statistically significant 77.8% reduction in clinical seizures compared to baseline over the 8-week treatment period, with 24% of participants achieving seizure freedom [3] - The treatment was well-tolerated, with a low discontinuation rate of 10% and most adverse events being mild [3] Early Onset of Action - The drug demonstrated early clinical response with median percent reductions in long episodes (LEs) and clinical seizures consistently observed throughout the treatment period [5][6] - Median percent reduction in LEs was 74.7% for both the first and second halves of the treatment, and 71.0% overall [6] Robust Efficacy Across Disease Severity - RAP-219 provided consistent responses regardless of baseline disease severity, with 85.7% of patients with lower baseline LE frequency achieving a ≥30% reduction in LE frequency [7] - Seizure freedom rates were similar across different baseline clinical seizure frequencies, indicating broad efficacy [7] Improvements in Quality of Life - Treatment with RAP-219 improved seizure intensity, recovery time, concentration ability, and reduced seizure interference with daily activities, suggesting potential enhancements in patients' quality of life [8][9] Future Development Plans - The company plans to hold an end-of-Phase 2 meeting with the FDA and anticipates initiating two pivotal Phase 3 trials in Q3 2026 [2] - Rapport is also developing a long-acting injectable formulation of RAP-219 to improve patient adherence [16] Broader Applications - Beyond epilepsy, RAP-219 is being evaluated in a Phase 2 trial for bipolar mania, with topline results expected in early 2027 [17]
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures